Case Report: Myiasis due to Cochliomyia hominivorax and Dermatobia hominis: Clinical and Pathological Differences between Two Species in Northern Peru

Virgilio E. Failoc-Rojas,1,2,4* Carolina Molina-Ayasta,2 Jaime Salazar-Zuloeta,1 Abel Samame,3 and Heber Silva-Díaz4

1 School of Medicine, Universidad Nacional Pedro Ruíz Gallo, Lambayeque, Peru; 2 Centro de Epidemiología Clínica y Medicina Basada en Evidencias, Universidad San Martín de Porres, Lambayeque, Peru; 3 Laboratorio de Neurociencia y Comportamiento, Universidad Peruana Cayetano Heredia, Lima, Peru; 4 Laboratorio de Parasitología, Metaxénicas y Zoonosis, Hospital Regional Lambayeque, Lambayeque, Peru

Abstract. Infestations caused by fly larvae (Myiasis) have been observed in patients with risk factors and in tropical zones. The aim of our study was to describe the clinical and epidemiological aspects and the risk factors associated with the occurrence of obligatory myiasis, as well as the therapeutic approach to patients. We identified the cases of myiasis diagnosed in two referral hospitals in northern Peru from January 2012 to December 2015 and included patients in whom larval development and a compatible clinical profile were observed. Epidemiological, clinical, analytical, diagnostic, therapeutic, and follow-up data were collected from clinical files. Nine clinical cases were compatible with a diagnosis of myiasis; of these, two were pediatric patients, one was a middle-aged adult, and six were elderly patients. Four of the nine patients were male. The identified species were Dermatobia hominis and Cochliomyia hominivorax. The therapeutic approach included antiparasitic therapy with ivermectin, antibacterial, and in some cases, anti-inflammatory drugs. Dermatobia hominis and C. hominivorax are the predominant species causing myiasis in northern Peru.

INTRODUCTION

Myiasis is the development of fly larvae that infest the skin, necrotic tissues, and natural cavities in living persons.1–3 The fly larvae belong to the order Diptera, class Insecta,1 and the species vary depending on the geographic area. Myiasis cases are classified into three categories, depending on the causative agent: obligatory myiasis, caused by Dermatobia hominis, Cochliomyia hominivorax, Cordylobia, Oestrus ovis, Wohlfahrtia magnifica, or Hypoderma bovis1–4; facultative myiasis, by Calliphora vicina, Phaenicia sericata, Lucilia ilustris, or Sarcophaga haemorrhoidalis; and accidental myiasis, by Musca domestica, Drosophila sp., Chrysomya albiceps, Eratitis tenax, Piophila casei, among others.4–8

Factors contributing to the development of human myiasis include low socioeconomic status, unhealthy environment, alcoholism, neurological disease, lack of personal hygiene, presence of varicose ulcers, advanced stages of cancer, malnutrition, immunosuppression, sexually transmitted diseases, diabetes, oral cavity lesions, advanced age, and animal husbandry.5–7

Human myiasis has been reported on a few occasions in Peru. Beltrán9 reported three cases of ophthalmomyiasis by O. ovis, whereas Miranda10 described cutaneous myiasis by C. hominivorax (five cases) and Stomoxys calcitrans (one case); on the other hand, Espinoza2 reported an oral myiasis by C. hominivorax. However, this infestation has been poorly studied in this country. It can occur in various ways, with different levels of severity and a difficult therapeutic approach. In this regard, the aim of our study was to describe the clinical and epidemiological aspects and the risk factors associated with obligatory myiasis (one of the most frequently reported in Peru), as well as its therapeutic approach.

METHODS

A retrospective study was performed on all patients admitted with a confirmed diagnosis of myiasis (CIE-10: B87) at Hospital Regional Lambayeque and Hospital Nacional Almanzor Aguinaga Asenjo (both category III hospitals) from January 2012 to December 2015. The diagnosis was made on clinical presentation, removal of larvae, and evidence of larval development and morphology.

Clinical (disease duration, type of presentation, signs, and symptoms), epidemiological (place of origin), therapeutic (drugs used), and follow-up data were collected from patients’ medical histories (age, gender, and comorbidities), and identification of each type of myiasis was based on the larval morphology (tracheal trunks, dorsum, etc.), as described in literature8; briefly, different larval specimens were collected into saline and sent to the Laboratory of Parasitology of the Hospital Regional Lambayeque for entomologic identification by taxonomic keys that emphasize certain morphological features8 (Figure 1). The study protocol was approved by the ethics committee of Hospital Regional Lambayeque. The authors claim to respect the confidentiality of the data and the protection of anonymity of patients.

RESULTS

As shown in Table 1, in this retrospective study we reported nine clinical cases compatible with the diagnosis of myiasis, which were categorized into age groups: pediatric (two cases; mean age of 3 years), middle-aged adults (one 52-year-old case), and elderly patients (six cases; mean age of 73.5 years). Four of these cases were male, and patients’ interviews revealed that only four of nine cases were contracted in the tropical rain forest, whereas the others were from the coastal area of Peru.

We reported five cases of myiasis caused by C. hominivorax, and four cases caused by D. hominis. Of the five cases caused by C. hominivorax, four were related to comorbidities such as cancer (invasive squamous cell carcinoma, laryngeal cancer, squamous cell carcinoma, and breast cancer), whereas the remaining case had a clinical history of tuberculosis. On the other hand, two of the infestations caused by D. hominis were pediatric cases without established comorbidities.

In one case (nasal myiasis), the larva was asphyxiated with Ocimum basilicum “basi,” manually removed, and then the
patient received antibiotic treatment. The therapeutic approach to myiasis varied among the cases; however, antibacterial (beta lactams and quinolones), antiparasitic (ivermectin), and anti-inflammatory therapy were common. In some cases by *C. hominivorax*, surgical cleansing was used. See additional details in Table 1.

**DISCUSSION**

This report discloses a series of myiasis cases by two obligate parasites, *C. hominivorax* and *D. hominis*, from two referral hospitals in the northern macro region of Peru in recent years (2012–2015).

Human myiasis remains a neglected disease, i.e., poorly studied and not adequately treated by health authorities; however, a number of cases with difficult approaches have been reported, from oral, cutaneous, ophthalmomyiasis, tracheostomal, to nosocomial myiasis. Frequent complications are bacterial superinfection that causes septicemia, tetanus, and cerebral myiasis causing death.

In this study, we report cases of cutaneous, scalp, nasal, and tracheostomal myiasis, all of positive clinical course but with high symptoms. Patients with myiasis caused by *D. hominis* had severe pain, phlogosis in skin lesions, active bleeding, and cutaneous abscesses, whereas in the cases caused by *C. hominivorax*, patients had a history of tuberculosis, squamous cell carcinoma, or laryngeal or breast cancer.

All the cases of cutaneous myiasis caused by *D. hominis* were contracted in areas with tropical climates, all with a history of insect bite, which subsequently showed phlogosis signs in the wound; this is compatible with the clinical and life cycle of this type of Diptera. On the other hand, the myiasis caused by *C. hominivorax* affected patients with old, necrotic, and exposed skin lesions, such as squamous cell carcinomas or tracheostomy patients; i.e., unlike the life cycle of *D. hominis* (Figure 2), it did not require a vector for the development of myiasis, merely an exposed wound.

Because *D. hominis* is transmitted by mosquitoes or other hematophagous arthropods, it causes problems for people living in tropical areas, where these vectors, which carry the larval eggs on their bodies to the host, abound. By contrast, *C. hominivorax*, whose transmission is direct, could present a wider geographical distribution in the northern regions of Peru.

As shown by our data, this parasitic infestation mostly affected either elderly or very young patients. Interestingly, children were most commonly infested by *D. hominis*, whereas adults (with comorbidities of necrosis such as cancer and tuberculosis) were most affected by *C. hominivorax*.

In this context, myiasis must be managed by the authorities as a sanitary problem in this region. Furthermore, public policies in animal health are also necessary for the management of myiasis in the agricultural field as domestic and wild animals are reservoirs of this disease and tourism to endemic areas has become increasingly common. Finally, the diagnosis of myiasis is clinical and epidemiological, and should be duly recognized in health care centers for suitable treatment and control.
<table>
<thead>
<tr>
<th>Case</th>
<th>Age (gender)</th>
<th>Patient comorbidities</th>
<th>Description</th>
<th>Injury features</th>
<th>Received treatment</th>
<th>Isolated species</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>74 (M)</td>
<td>Uncontrolled hypertension</td>
<td>Presented a snakebite on the right foot 5 days before symptoms</td>
<td>Two phlogotic and furunculoid nodules with small pores on the right foot, where movement of larvae was observed by ultrasound</td>
<td>Ciprofloxacin 200 mg, IV every 12 hour; Oxacillin 2 g, IV every 4 hour; Chlorphenamine 4 mg, 1 tab, PO</td>
<td>Dermatobia hominis</td>
</tr>
<tr>
<td>2</td>
<td>52 (F)</td>
<td>None</td>
<td>Presented an insect bite on the buttock and, a month later, a local abscess was observed</td>
<td>Painful bleeding boil-like lesion on buttock; The diagnosis was made by ultrasound; lesions (3 mm) with surrounding edema (8-10 mm) and larvae were observed</td>
<td>Cefazolin 500 mg, IV every 8 hour; Glucose 5 × 1,000 mL; Mupirocin ointment in ampule applied twice a day</td>
<td>Dermatobia hominis</td>
</tr>
<tr>
<td>3</td>
<td>2 (F)</td>
<td>Prematurity, low psychomotor development</td>
<td>Presented an insect bite on the buttock a month before hospitalization</td>
<td>Painful abscess (2 by 2 cm) on the buttock with excoration and larvae emerging from the lesion</td>
<td>Cefazolin 300 mg, IV every 8 hour for 11 days; Ivermectin 9 drops (single dose); Drainage by surgery; Exeresis of the toe of the infiltrated foot; Cefazolin 1 g Gentamicin 80 g, IV every 8 hour</td>
<td>Dermatobia hominis</td>
</tr>
<tr>
<td>4</td>
<td>71 (M)</td>
<td>Invasive squamous cell carcinoma of the distal phalanx</td>
<td>Treated for an increase of the skin eruption on the left foot</td>
<td>Phlogotic and erythematous skin eruption on the fifth toe of the left foot</td>
<td>Ivermectin 9 drops (single dose); Exeresis of the toe of the infiltrated foot</td>
<td>Cochliomyia hominivorax</td>
</tr>
<tr>
<td>5</td>
<td>4 (M)</td>
<td>None</td>
<td>Presented an erythematous and pruritic scalp lesion a month before</td>
<td>Scabby lesion (3 by 2 cm) with purulent discharge on the frontal region</td>
<td>Hydroxyzine 15 days; Ivermectin single dose</td>
<td>Dermatobia hominis</td>
</tr>
<tr>
<td>6</td>
<td>71 (F)</td>
<td>History of tuberculosis</td>
<td>Facial cellulite; anterior epistaxis and referred nasal pain.</td>
<td>Nasal pain; respiratory distress and epistaxis.</td>
<td>Ciprofloxacin 200 mg, IV every 8 hour; Clindamycin 600 mg, IV every 8 hour</td>
<td>Cochliomyia hominivorax</td>
</tr>
<tr>
<td>7</td>
<td>67 (F)</td>
<td>Laryngeal cancer (III)</td>
<td>Tracheostomy due to respiratory distress</td>
<td>Presence of larvae in the place of tracheostomy; cervical abscess surrounded by necrotic tissue, brown discharge, and traces of blood</td>
<td>Ivermectin 14 mg, (60 drops) PO, ceftriaxone 2 g/d PO and metronidazole 500 mg, IV every 8 hour</td>
<td>Cochliomyia hominivorax</td>
</tr>
<tr>
<td>8</td>
<td>85 (M)</td>
<td>Arterial hypertension; squamous cell carcinoma; nasal inverted papilloma and history of nasal myiasis</td>
<td>History of nasal polyps (surgically intervened three times); necrotic lesion on the upper third of the nose</td>
<td>Presence of larvae in the necrotic area on the upper third of the nose; intense pain</td>
<td>Ivermectin 3 mg, two tablets in 2 days; surgical cleansing</td>
<td>Cochliomyia hominivorax</td>
</tr>
<tr>
<td>9</td>
<td>73 (F)</td>
<td>Invasive left breast cancer (III) Diabetes mellitus II</td>
<td>Ulcerated lesion with necrosis, irregular borders and phlogosis on nipple; serosanguineous discharge and larvae emerging from the lesion</td>
<td>Presence of larvae in the lesion and necrotic area on the left breast; itching and pain</td>
<td>Ivermectin 14 mg (60 drops) PO for 2 days; Ciprofloxacin 200 mg, IV every 12 hour; Clindamycin 600 mg, IV every 8 hour</td>
<td>Cochliomyia hominivorax</td>
</tr>
</tbody>
</table>

M = male; F = female. All cases progressed favorably during hospitalization.
Acknowledgments: We thank Suzanna Rojas Thompson for her constructive comments on an earlier version of this manuscript and Boris Castañeda for his help with graphics and designs.

Authors’ addresses: Virgilio E. Failoc-Rojas, School of Medicine, Universidad Nacional Pedro Ruiz Gallo, Lambayeque, Peru, and Laboratorio de Parasitología, Metaxénicas y Zoonosis, Hospital Regional Lambayeque, Lambayeque, Peru, E-mail: virgiliofr@gmail.com. Carolina Molina-Ayasta, School of Medicine, Universidad San Martin de Porres, Lambayeque, Peru, E-mail: caritomolinaayasta@gmail.com. Jaime Salazar-Zuloeta, School of Medicine, Universidad Nacional Pedro Ruiz Gallo, Lambayeque, Peru, E-mail: jaimesalazarzuloeta@yahoo.es. Abel Samame, Laboratorio de Neurociencia y Comportamiento, Universidad Peruana Cayetano Heredia, Lima, Peru, E-mail: abel.samame@neurocienciaperu.org. Heber Silva-Díaz, Laboratorio de Parasitología, Metaxénicas y Zoonosis, Hospital Regional Lambayeque, Lambayeque, Peru, E-mail: h.silvadiaz@hotmail.com.

REFERENCES


Figure 2. Cycle according to the type of myiasis: Cochliomyia hominivorax and Dermatobia hominis. This figure appears in color at www.ajtmh.org.